Evidence map›Paper›PMID 41439947›Full record

ArticleDiseases (Basel, Switzerland)2025

Establishment of a Flow Cytometry Protocol for Binarily Detecting Circulating Tumor Cells with EGFR Mutation.

Cheng-Yu Chang, Chia-Chun Tu, Shian-Ren Lin, Chih-Hao Fang, Po-Wei Tseng, Wan-En Liao, Li-Yun Huang, Shiu-Lan Wang, Wan-Yu Lai, Yee Chao and 2 more

Abstract read
In one paragraph

Article in Diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Cheng-Yu ChangDivision of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.ORCID 0000-0002-7196-3504
Chia-Chun TuFullHope Biomedical Co., Ltd., New Taipei City 241405, Taiwan.ORCID 0000-0002-3862-9950
Shian-Ren LinFullHope Biomedical Co., Ltd., New Taipei City 241405, Taiwan.ORCID 0000-0002-4160-2361
Chih-Hao FangFullHope Biomedical Co., Ltd., New Taipei City 241405, Taiwan.
Po-Wei TsengFullHope Biomedical Co., Ltd., New Taipei City 241405, Taiwan.
Wan-En LiaoFullHope Biomedical Co., Ltd., New Taipei City 241405, Taiwan.
Li-Yun HuangFullHope Biomedical Co., Ltd., New Taipei City 241405, Taiwan.
Shiu-Lan WangFullHope Biomedical Co., Ltd., New Taipei City 241405, Taiwan.
Wan-Yu LaiFullHope Biomedical Co., Ltd., New Taipei City 241405, Taiwan.
Yee ChaoFullHope Biomedical Co., Ltd., New Taipei City 241405, Taiwan.
Yen-Ling ChiuDivision of Nephrology, Department of Medicine, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.ORCID 0000-0003-4504-5571
Jan-Mou LeeFullHope Biomedical Co., Ltd., New Taipei City 241405, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with EGFR-mutated non-small cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase inhibitors (TKIs), but current EGFR mutation profiling relies on invasive tumor biopsies. Developing less invasive approaches, particularly proteomic evaluation of circulating tumor cells (CTCs) for EGFR mutation profiling, remains crucial.

methodsA flow cytometry method for detecting EGFR

resultsThe gating strategy was defined by CD45

conclusionsThis study introduces a feasible, less invasive proteomic approach for binarily detecting EGFR mutations in CTCs, offering a novel means for patient identification.

Indexed as

circulating tumor cellepidermal growth factorflow cytometrynon-small-cell lung cancertargeted therapy

Identifiers

PMID41439947
PMCPMC12731806

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.